================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                          ----------------------------


                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of report (Date of earliest event reported): July 18, 2006

                           Critical Therapeutics, Inc.
               (Exact Name of Registrant as Specified in Charter)

        Delaware                         000-50767               04-3523569
(State or Other Jurisdiction            (Commission            (IRS Employer
    of Incorporation)                   File Number)         Identification No.)


      60 Westview Street, Lexington, Massachusetts                   02421
       (Address of Principal Executive Offices)                    (Zip Code)

       Registrant's telephone number, including area code: (781) 402-5700

                                 Not applicable
          (Former Name or Former Address, if Changed Since Last Report)

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))

================================================================================




Item 8.01.  Other Events.

On July 18, 2006, Critical Therapeutics, Inc. (the "Company") issued a press
release announcing that Anne M. Fields has resigned as Vice President of Sales.
The full text of the Company's press release is filed as Exhibit 99.1 to this
Form 8-K and is incorporated herein by reference.

Item 9.01.  Financial Statements and Exhibits.

       (d)  Exhibits

            See Exhibit Index attached hereto.



                                        1



                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



Date:  July 18, 2006                      CRITICAL THERAPEUTICS, INC.
                                          By:   /s/Frank E. Thomas
                                                --------------------------------
                                                Frank E. Thomas
                                                President



                                       2



                                  EXHIBIT INDEX


Exhibit No.                          Description
------------------------             -------------------------------------------


99.1                                 Press Release, dated July 18, 2006